Skip to NavigationSkip to content

NOACs

NICE recommends Daiichi’s Lixiana for blood clots

Daiichi Sankyo
Daiichi has earned NICE approval for its newly-launched drug Lixiana

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug Lixiana as a treatment for clots in the legs and lungs.

The NICE decision comes just days after Daiichi launched Lixiana (edoxaban) in the UK, and shortly after the Japanese firm earned European approval for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults and the prevention of stroke and clots in adults with

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches